KCM Investment Advisors LLC Buys 394 Shares of Eli Lilly and Company (NYSE:LLY)

KCM Investment Advisors LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 1.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 38,668 shares of the company’s stock after buying an additional 394 shares during the period. Eli Lilly and Company comprises about 1.2% of KCM Investment Advisors LLC’s portfolio, making the stock its 28th biggest holding. KCM Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $34,258,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its holdings in Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after acquiring an additional 1,620 shares in the last quarter. Trillium Asset Management LLC bought a new stake in Eli Lilly and Company during the 1st quarter worth $261,000. M&G Plc bought a new stake in Eli Lilly and Company during the 1st quarter worth $8,896,000. Towercrest Capital Management bought a new stake in Eli Lilly and Company during the 1st quarter worth $625,000. Finally, Councilmark Asset Management LLC bought a new stake in Eli Lilly and Company during the 1st quarter worth $700,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 3.4 %

Shares of Eli Lilly and Company stock traded down $27.01 during mid-day trading on Friday, hitting $759.22. The stock had a trading volume of 1,564,390 shares, compared to its average volume of 3,112,148. The firm has a 50-day moving average of $885.79 and a two-hundred day moving average of $869.71. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a market cap of $720.74 billion, a P/E ratio of 82.43, a price-to-earnings-growth ratio of 3.07 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the prior year, the company posted $0.10 earnings per share. The business’s revenue was up 20.4% compared to the same quarter last year. Sell-side analysts forecast that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.68%. Eli Lilly and Company’s payout ratio is 56.22%.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on LLY shares. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Guggenheim increased their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Citigroup raised their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.